KBI Biopharma and Argonaut Manufacturing Services form strategic alliance

The companies say the arrangement provides the seamless manufacturing by combining KBI’s leading drug development and biologics manufacturing services with Argonaut’s experience in sterile fill-finish.

The alliance reinforces both companies’ commitment to supporting customers in bringing clinical and commercial therapies to patients quickly, safely, and efficiently.

KBI and Argonaut say biopharmaceutical organizations are expected to benefit from this strategic collaboration through accelerated timelines and the scalable manufacturing capacities offered by both organizations.

J.D. Mowery, president and CEO of KBI Biopharma said: “We have always been committed to delivering innovative solutions that accelerate the development and manufacturing of life-saving therapeutics. Our state-of-the-art facilities and world-class team have consistently pushed the boundaries of what is possible in biopharmaceutical development.”

He continued: “Similarly, Argonaut has established itself as a trusted provider in the industry, known for its cutting-edge technologies and exceptional track record in drug product manufacturing. Their commitment to quality and efficiency aligns perfectly with our values and vision. This collaboration represents a new era of collaboration and innovation in the biopharma industry.”

In January 2023, Argonaut announced a capital investment focused on the significant expansion of its Carlsbad, CA manufacturing facilities with increased capacity and scale, and this agreement with KBI furthers its commitment to continual growth.

Leave a Reply

Your email address will not be published. Required fields are marked *